Bious Life — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Bious Life is a private, pre-revenue platform company specializing in 3D cell culture technology. Its core innovation is a proprietary 3D fibre printing (3Df) method that creates scaffolds with tunable, round-fibre morphology to better emulate natural tissue environments. The company sells customizable scaffolds directly to researchers and has potential in the growing markets for organ-on-chip models and advanced cell-based assays. Its current focus appears to be on technology validation and early commercial engagement in the research tools sector.

MicrobiomeDiagnostics

Technology Platform

Proprietary 3D fibre printing (3Df) technology, a hybrid of solvent-free/solvent-based electrospinning and additive manufacturing, used to create tunable 3D cell culture scaffolds that mimic the natural extracellular matrix.

Opportunities

The global 3D cell culture market is growing rapidly due to demand for better disease models in drug discovery.

Bious Life's tunable, ECM-mimicking scaffolds are well-positioned for applications in high-value areas like organ-on-chip development and complex disease modeling (e.g., cancer).

Selling its proprietary 3Df printers also opens a B2B equipment revenue stream.

Risk Factors

The company faces intense competition from large, established life science tools vendors and must prove its technology's superiority to drive adoption.

As a likely pre-revenue startup, it carries significant financial sustainability risk, needing to convert pilot interest into recurring sales before depleting capital.

Scaling consistent manufacturing is another key operational challenge.

Competitive Landscape

Bious Life competes in the crowded 3D cell culture market against giants like Corning (Matrigel, AlgiMatrix), Merck, and Thermo Fisher, as well as numerous startups. Its differentiation lies in the unique round-fibre, tunable morphology created by its hybrid printing process, contrasting with common hydrogel or aligned-fibre alternatives. Success depends on proving this morphology offers tangible functional advantages for researchers.

More companies in Europe - Other →